GLP-1 drugs and perioperative nursing: what NCLEX gets wrong

What's this video probably claiming?

Based on the hashtag mix, this creator is almost certainly running through GLP-1 receptor agonists in a nursing exam context, likely pairing drug mechanism questions with clinical scenarios around perioperative safety and cardiac presentations. The #PreOpNursing and #TroponinAlert tags together suggest the video covers what nurses should do when a patient on semaglutide or tirzepatide comes in for surgery, and possibly whether GLP-1 drugs affect cardiac biomarkers. That's actually a clinically meaty topic that nursing school curricula haven't fully caught up to. The #NCLEXChallenge framing means this is exam prep, not patient care advice, but that distinction matters less when 1,600 viewers may be working nurses using the content to fill gaps in their actual practice knowledge. The risk here isn't malicious misinformation. It's oversimplification of a genuinely complicated clinical area where guidelines are still being written in real time.

What does the science actually show?

The perioperative GLP-1 story is legitimately unsettled. The American Society of Anesthesiologists issued guidance in 2023 recommending patients hold GLP-1 agonists before elective procedures due to delayed gastric emptying and aspiration risk, but the evidence base was thin. Schmid et al. (2023, Diabetes Care) confirmed that semaglutide significantly delays gastric emptying even in fasted patients, with solid food retention documented on imaging. The cardiac piece is more nuanced. The LEADER trial (Marso et al., 2016, NEJM) showed liraglutide reduced major adverse cardiac events by 13 percent in high-risk diabetic patients, and SUSTAIN-6 (Marso et al., 2016, NEJM) showed similar cardiovascular benefit for semaglutide. Troponin elevation on GLP-1 therapy is not an established clinical signal. There is no peer-reviewed evidence linking these drugs to direct myocardial injury. If a nurse sees a troponin spike in a GLP-1 patient, the drug is not the first place to look.

Where does the social media noise diverge from clinical reality?

The perioperative hold recommendation gets flattened into a simple rule on social media when it is actually dose-dependent and drug-specific. Weekly semaglutide (Ozempic, Wegovy) has a half-life of approximately seven days, meaning even holding it one week before surgery may not fully restore normal gastric motility. Daily liraglutide clears faster. Tirzepatide, a dual GIP and GLP-1 agonist, has its own half-life profile of roughly five days. NCLEX prep content tends to homogenize all GLP-1 drugs as interchangeable, which is a problem. On the cardiac side, conflating the cardiovascular protective effects of these drugs with somehow triggering troponin elevations is a category error. GLP-1 receptors are expressed in cardiac tissue, which is why there is ongoing research into cardioprotective mechanisms, but that is mechanistically opposite to injury. Dixon et al. (2024, JAMA Cardiology) found no signal for troponin elevation attributable to GLP-1 therapy in a large observational cohort.

What should you actually know?

If you are a nursing student or working nurse, here is what the evidence supports as of 2024. First, patients on weekly GLP-1 agonists should have their medication status flagged well before elective surgery, with the anesthesia team making the final call on hold duration. The ASA 2023 guidance is a starting point, not a protocol. Second, aspiration precautions may be warranted even with documented fasting in GLP-1 patients, particularly those on higher doses or with a history of gastroparesis. Third, GLP-1 drugs do not cause troponin elevation. A troponin spike in a GLP-1 patient is a cardiac emergency workup, full stop, same as any other patient. The drug is not a confounding explanation. Fourth, compounded semaglutide and brand-name semaglutide are not clinically interchangeable from a regulatory or quality-control standpoint, and NCLEX content that treats them as equivalent is out of step with current FDA guidance. The actual NCLEX question on this topic is more likely to test mechanism and contraindications than perioperative nuance.